出生后FXR表达下降协调小鼠新生β细胞量与微生物胆汁酸代谢成熟
该研究探讨了微生物胆汁酸代谢与FXR信号在新生β细胞发育中的作用。小鼠β细胞FXR表达出生后下降,与微生物胆汁酸成熟同步;持续表达FXR导致β细胞量减少和高血糖。机制涉及CASP6介导的凋亡,人类数据支持FXR/CASP6在2型糖尿病中的作用。
要点
- β细胞FXR表达出生后生理性下降,与肠道菌群胆汁酸成熟平行。
- 持续表达FXR限制β细胞量增长并导致断奶后高血糖。
- CASP6是FXR下游关键靶点,抑制CASP6可部分逆转表型。
核心结论
- 新生β细胞中FXR-CASP6信号下降是对微生物胆汁酸代谢成熟的程序性宿主反应,维持出生后β细胞量正常发育和成年血糖稳态。
研究设计与样本
- 小鼠围产期不同阶段检测胰岛FXR水平,比较肠道菌群和胆汁酸谱变化,以无菌小鼠胆汁酸为对照。
- 构建出生后持续表达FXR的β细胞特异性Nr1h4敲入小鼠(βFxrKI),进行形态和功能分析。
- 利用单细胞RNA测序和单细胞ATAC测序研究FXR下游调控,谱系追踪评估β细胞命运。
- 应用孟德尔随机化和人类胰岛蛋白质组数据分析人类糖尿病中的病理相关性。
主要发现
- 小鼠β细胞FXR阳性比例在胚胎第18.5天为29.1 ± 3.1%,出生后3周降至4.2 ± 2.4%(p<0.001)。
- 非结合胆汁酸比例在1周龄为0.9 ± 0.6%,3周龄升至14.0 ± 5.6%(p<0.05),与FXR激动性胆汁酸上升平行。
- βFxrKI小鼠1周龄β细胞量约为对照70%,8周龄仅为对照15%;断奶时随机血糖15.2 ± 1.7 mmol/l vs 对照7.7 ± 0.5 mmol/l(p<0.001)。
- βFxrKI小鼠β细胞凋亡在1、2、3周龄分别较对照增加1.95、1.79、3.27倍,并出现β细胞身份改变。
- 人类2型糖尿病供体胰岛FXR水平为0.646 ± 1.140 a.u. vs 无糖尿病供体-0.039 ± 1.257 a.u.(p=0.0371);CASP6为-1.325 ± 0.381 a.u. vs -1.575 ± 0.307 a.u.(p=0.011)。
临床怎么用
- 新生期β细胞FXR表达下降是生理性成熟过程,持续高FXR可能损害β细胞量发育。
- CASP6抑制剂或抗生素干预可部分恢复βFxrKI小鼠表型,提示潜在干预靶点。
- 人类胰岛FXR/CASP6水平升高与2型糖尿病相关,孟德尔随机化支持其因果效应。
局限性
- 研究主要基于小鼠模型,人类数据为关联和孟德尔随机化分析,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diet switch during weaning induces gut microbiome maturation, accompanied by the formation of adequate functional beta cell mass. Bile acid (BA), an essential microbial metabolite, regulates host glucose homeostasis by binding to its main receptor, farnesoid X receptor (FXR, encoded by NR1H4). However, the precise roles of microbial BA metabolism and FXR signalling in neonatal beta cell development are still unclear. METHODS: Islet FXR levels were determined at different perinatal stages. Postnatal changes in gut microbiome and BA profiles were examined in mice, with changes in germ-free mouse BAs serving as the control. We genetically modified beta cells to sustain FXR expression after birth (using Nr1h4-knockin [βFxrKI] mice) and performed morphological and functional analysis on murine islets. Single-cell RNA-seq and single-cell assay for transposase-accessible chromatin sequencing of islet cells were used to study FXR-mediated downstream regulation in islets. Lineage tracing was performed to evaluate beta cell fate transition. Mendelian randomisation (MR) and human islet proteomics data analysis were applied to study the pathological relevance in human diabetes. RESULTS: FXR expression in beta cells declined after birth (positive cell proportion, 29.1 ± 3.1% at embryonic day 18.5 vs 4.2 ± 2.4% at 3 weeks postnatal in mice, p<0.001). This physiological change paralleled the ascending of FXR-agonistic BAs derived from gut microbiome maturation (unconjugated BA proportion, 0.9 ± 0.6% at 1 week vs 14.0 ± 5.6% at 3 weeks, p<0.05). βFxrKI mice had limited beta cell mass growth (approximately 70% of the control level at 1 week of age and only 15% of the control level at 8 weeks of age) and developed high blood glucose levels by weaning (random blood glucose, 15.2 ± 1.7 mmol/l in βFxrKI vs 7.7 ± 0.5 mmol/l in control, p<0.001), mainly resulting from elevated cell apoptosis (1.95-, 1.79-, and 3.27-fold increase vs control at 1, 2 and 3 weeks, respectively) and altered beta cell identity. Casp6 was identified as a key downstream target in beta cell FXR. Intervention with antibiotics or a specific caspase-6 (CASP6) inhibitor partially recovered the phenotypes of βFxrKI mice. Further validation in humans showed that islet FXR/CASP6 levels were elevated in individuals with type 2 diabetes (FXR, -0.039 ± 1.257 a.u. in donors without diabetes vs 0.646 ± 1.140 a.u. in donors with diabetes, p=0.0371; CASP6, -1.575 ± 0.307 a.u. in donors without diabetes vs -1.325 ± 0.381 a.u. in donors with diabetes, p=0.011). MR analysis further supported the effect of human islet FXR expression in elevating HbA1c (β=0.006, p<0.001) with lowering fasting insulin level (β=-0.009, p=0.02) and the effect of CASP6 expression in enhancing 2 h glucose (β=0.039, p=0.01). CONCLUSIONS/INTERPRETATION: The declining FXR-CASP6 signals in neonatal beta cells could serve as a programmed host response to the maturing gut microbial BA metabolism to maintain normal postnatal beta cell mass development and ensure glycaemic homeostasis in adults. DATA AVAILABILITY: Raw data of scRNA-seq and scATAC-seq are deposited in the Gene Expression Omnibus (GEO) database under the accession number GSE241408. The code used in this Mendelian randomisation study is publicly available at https://github.com/Angela-linyt/Gene_Glu_MR.git .
引用
- Fu C, Li T, Hao Y, et al. Declining FXR expression coordinates neonatal beta cell mass development with microbial bile acid metabolism maturation in mice. Diabetologia. 2025. PMID: 41381886. doi:10.1007/s00125-025-06618-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。